Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5698226 (Pediatric) | GLAXOSMITHKLINE LLC | Water-dispersible tablets |
Jul, 2012
(11 years ago) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-159) | May 18, 2018 |
Market Authorisation Date: 08 September, 2000
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7919115 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jan, 2029
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9339504 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(4 years from now) | |
US8840925 | GLAXOSMITHKLINE LLC | Orally disintegrating tablet compositions of lamotrigine |
Jul, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-159) | May 18, 2018 |
Market Authorisation Date: 08 May, 2009
Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9144547 | GLAXOSMITHKLINE LLC | Oral dosage form for controlled drug release |
Sep, 2023
(7 months ago) | |
US8637512 | GLAXOSMITHKLINE LLC | Formulations and method of treatment |
Jun, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | May 29, 2012 |
New Indication(I-644) | Apr 25, 2014 |
New Indication(I-622) | Jan 29, 2013 |
Pediatric Exclusivity(PED) | Nov 29, 2012 |
Market Authorisation Date: 29 May, 2009
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL